O	0	10	Suppressed	Suppress	VBN	B-NP
O	11	25	transformation	transformation	NN	I-NP
O	26	29	and	and	CC	O
O	30	37	induced	induce	VBD	B-VP
O	38	53	differentiation	differentiation	NN	B-NP
O	54	56	of	of	IN	B-PP
O	57	60	HER	HER	NN	B-NP
O	60	61	-	-	HYPH	B-NP
O	61	62	2	2	CD	I-NP
O	62	63	/	/	SYM	I-NP
O	63	66	neu	neu	NN	I-NP
O	66	67	-	-	HYPH	O
O	67	81	overexpressing	overexpresse	VBG	B-VP
B-Cell	82	88	breast	breast	NN	B-NP
I-Cell	89	95	cancer	cancer	NN	I-NP
I-Cell	96	101	cells	cell	NNS	I-NP
O	102	104	by	by	IN	B-PP
O	105	111	emodin	emodin	NN	B-NP
O	111	112	.	.	.	O

O	114	117	The	The	DT	B-NP
O	118	131	amplification	amplification	NN	I-NP
O	132	135	and	and	CC	I-NP
O	136	150	overexpression	overexpression	NN	I-NP
O	151	153	of	of	IN	B-PP
O	154	157	the	the	DT	B-NP
O	158	161	HER	HER	NN	I-NP
O	161	162	-	-	HYPH	B-NP
O	162	163	2	2	CD	I-NP
O	163	164	/	/	SYM	I-NP
O	164	167	neu	neu	NN	I-NP
O	168	173	proto	proto	AFX	O
O	173	174	-	-	HYPH	O
O	174	182	oncogene	oncogene	NN	B-NP
O	182	183	,	,	,	O
O	184	189	which	which	WDT	B-NP
O	190	197	encodes	encode	VBZ	B-VP
O	198	201	the	the	DT	B-NP
O	202	210	tyrosine	tyrosine	NN	I-NP
O	211	217	kinase	kinase	NN	I-NP
O	218	226	receptor	receptor	NN	I-NP
O	227	234	p185neu	p185neu	NN	I-NP
O	234	235	,	,	,	O
O	236	240	have	have	VBP	B-VP
O	241	245	been	be	VBN	I-VP
O	246	254	observed	observe	VBN	I-VP
O	255	265	frequently	frequently	RB	B-ADVP
O	266	268	in	in	IN	B-PP
B-Cancer	269	275	tumors	tumor	NNS	B-NP
O	276	280	from	from	IN	B-PP
O	281	286	human	human	JJ	B-NP
B-Cancer	287	293	breast	breast	NN	I-NP
I-Cancer	294	300	cancer	cancer	NN	I-NP
O	301	309	patients	patient	NNS	I-NP
O	310	313	and	and	CC	O
O	314	317	are	be	VBP	B-VP
O	318	328	correlated	correlate	VBN	I-VP
O	329	333	with	with	IN	B-PP
O	334	338	poor	poor	JJ	B-NP
O	339	348	prognosis	prognosis	NN	I-NP
O	348	349	.	.	.	O

O	350	352	To	To	TO	B-VP
O	353	360	explore	explore	VB	I-VP
O	361	364	the	the	DT	B-NP
O	365	374	potential	potential	NN	I-NP
O	375	377	of	of	IN	B-PP
O	378	390	chemotherapy	chemotherapy	NN	B-NP
O	391	399	directed	direct	VBN	B-VP
O	400	402	at	at	IN	B-PP
O	403	406	the	the	DT	B-NP
O	407	415	tyrosine	tyrosine	NN	I-NP
O	416	422	kinase	kinase	NN	I-NP
O	423	425	of	of	IN	B-PP
O	426	433	p185neu	p185neu	NN	B-NP
O	433	434	,	,	,	O
O	435	437	we	we	PRP	B-NP
O	438	442	have	have	VBP	B-VP
O	443	448	found	find	VBN	I-VP
O	449	453	that	that	IN	B-SBAR
O	454	460	emodin	emodin	NN	B-NP
O	461	462	(	(	(	O
O	462	463	3	3	CD	B-NP
O	463	464	-	-	HYPH	I-NP
O	464	470	methyl	methyl	NN	I-NP
O	470	471	-	-	HYPH	I-NP
O	471	472	1	1	CD	I-NP
O	472	473	,	,	,	I-NP
O	473	474	6	6	CD	I-NP
O	474	475	,	,	,	I-NP
O	475	476	8	8	CD	I-NP
O	476	477	-	-	HYPH	I-NP
O	477	500	trihydroxyanthraquinone	trihydroxyanthraquinone	NN	I-NP
O	500	501	)	)	)	O
O	501	502	,	,	,	O
O	503	504	a	a	DT	B-NP
O	505	513	tyrosine	tyrosine	NN	I-NP
O	514	520	kinase	kinase	NN	I-NP
O	521	530	inhibitor	inhibitor	NN	I-NP
O	530	531	,	,	,	O
O	532	542	suppresses	suppress	VBZ	B-VP
O	543	562	autophosphorylation	autophosphorylation	NN	B-NP
O	563	566	and	and	CC	I-NP
O	567	587	transphosphorylation	transphosphorylation	NN	I-NP
O	588	598	activities	activity	NNS	I-NP
O	599	601	of	of	IN	B-PP
O	602	605	HER	HER	NN	B-NP
O	605	606	-	-	HYPH	B-NP
O	606	607	2	2	CD	I-NP
O	607	608	/	/	SYM	I-NP
O	608	611	neu	neu	NN	I-NP
O	612	620	tyrosine	tyrosine	NN	I-NP
O	621	627	kinase	kinase	NN	I-NP
O	627	628	,	,	,	O
O	629	638	resulting	result	VBG	B-VP
O	639	641	in	in	IN	B-PP
O	642	650	tyrosine	tyrosine	NN	B-NP
O	651	670	hypophosphorylation	hypophosphorylation	NN	I-NP
O	671	673	of	of	IN	B-PP
O	674	681	p185neu	p185neu	NN	B-NP
O	682	684	in	in	IN	B-PP
O	685	688	HER	HER	NN	B-NP
O	688	689	-	-	HYPH	B-NP
O	689	690	2	2	CD	I-NP
O	690	691	/	/	SYM	I-NP
O	691	694	neu	neu	NN	I-NP
O	694	695	-	-	HYPH	O
O	695	709	overexpressing	overexpresse	VBG	B-VP
B-Cell	710	716	breast	breast	NN	B-NP
I-Cell	717	723	cancer	cancer	NN	I-NP
I-Cell	724	729	cells	cell	NNS	I-NP
O	729	730	.	.	.	O

O	731	737	Emodin	Emodin	NN	B-NP
O	737	738	,	,	,	O
O	739	741	at	at	IN	B-PP
O	742	743	a	a	DT	B-NP
O	744	746	40	40	CD	I-NP
O	746	747	-	-	HYPH	I-NP
O	747	753	microM	microM	NN	I-NP
O	754	767	concentration	concentration	NN	I-NP
O	767	768	,	,	,	O
O	769	774	which	which	WDT	B-NP
O	775	784	repressed	repress	VBD	B-VP
O	785	793	tyrosine	tyrosine	NN	B-NP
O	794	800	kinase	kinase	NN	I-NP
O	801	803	of	of	IN	B-PP
O	804	811	p185neu	p185neu	NN	B-NP
O	811	812	,	,	,	O
O	813	824	efficiently	efficiently	RB	B-ADVP
O	825	834	inhibited	inhibit	VBD	B-VP
O	835	839	both	both	CC	O
O	840	849	anchorage	anchorage	NN	B-NP
O	849	850	-	-	HYPH	I-NP
O	850	859	dependent	dependent	JJ	I-NP
O	860	863	and	and	CC	I-NP
O	864	873	anchorage	anchorage	NN	I-NP
O	873	874	-	-	HYPH	B-NP
O	874	885	independent	independent	JJ	I-NP
O	886	892	growth	growth	NN	I-NP
O	893	895	of	of	IN	B-PP
O	896	899	HER	HER	NN	B-NP
O	899	900	-	-	HYPH	B-NP
O	900	901	2	2	CD	I-NP
O	901	902	/	/	SYM	I-NP
O	902	905	neu	neu	NN	I-NP
O	905	906	-	-	HYPH	O
O	906	920	overexpressing	overexpresse	VBG	B-VP
B-Cell	921	927	breast	breast	NN	B-NP
I-Cell	928	934	cancer	cancer	NN	I-NP
I-Cell	935	940	cells	cell	NNS	I-NP
O	940	941	.	.	.	O

O	942	949	However	However	RB	B-ADVP
O	949	950	,	,	,	O
O	951	954	the	the	DT	B-NP
O	955	965	inhibition	inhibition	NN	I-NP
O	966	969	was	be	VBD	B-VP
O	970	974	much	much	RB	B-ADJP
O	975	979	less	less	RBR	I-ADJP
O	980	989	effective	effective	JJ	I-ADJP
O	990	993	for	for	IN	B-PP
O	994	999	those	those	DT	B-NP
B-Cell	1000	1005	cells	cell	NNS	I-NP
O	1006	1016	expressing	express	VBG	B-VP
O	1017	1022	basal	basal	JJ	B-NP
O	1023	1029	levels	level	NNS	I-NP
O	1030	1032	of	of	IN	B-PP
O	1033	1040	p185neu	p185neu	NN	B-NP
O	1041	1046	under	under	IN	B-PP
O	1047	1050	the	the	DT	B-NP
O	1051	1055	same	same	JJ	I-NP
O	1056	1066	conditions	condition	NNS	I-NP
O	1066	1067	.	.	.	O

O	1068	1074	Emodin	Emodin	NN	B-NP
O	1075	1079	also	also	RB	B-ADVP
O	1080	1087	induced	induce	VBD	B-VP
O	1088	1103	differentiation	differentiation	NN	B-NP
O	1104	1106	of	of	IN	B-PP
O	1107	1110	HER	HER	NN	B-NP
O	1110	1111	-	-	HYPH	B-NP
O	1111	1112	2	2	CD	I-NP
O	1112	1113	/	/	SYM	I-NP
O	1113	1116	neu	neu	NN	I-NP
O	1116	1117	-	-	HYPH	O
O	1117	1131	overexpressing	overexpresse	VBG	B-VP
B-Cell	1132	1138	breast	breast	NN	B-NP
I-Cell	1139	1145	cancer	cancer	NN	I-NP
I-Cell	1146	1151	cells	cell	NNS	I-NP
O	1152	1154	by	by	IN	B-PP
O	1155	1165	exhibiting	exhibit	VBG	B-VP
O	1166	1167	a	a	DT	B-NP
O	1168	1181	morphological	morphological	JJ	I-NP
O	1182	1192	maturation	maturation	NN	I-NP
O	1193	1201	property	property	NN	I-NP
O	1202	1204	of	of	IN	B-PP
O	1205	1210	large	large	JJ	B-NP
O	1211	1215	lacy	lacy	NN	I-NP
B-Cellular_component	1216	1222	nuclei	nucleus	NNS	I-NP
O	1223	1233	surrounded	surround	VBN	B-VP
O	1234	1236	by	by	IN	B-PP
O	1237	1244	sizable	sizable	JJ	B-NP
B-Organism_substance	1245	1249	flat	flat	JJ	I-NP
I-Organism_substance	1250	1259	cytoplasm	cytoplasm	NN	I-NP
O	1260	1263	and	and	CC	B-PP
O	1264	1266	by	by	IN	B-PP
O	1267	1274	showing	show	VBG	B-VP
O	1275	1276	a	a	DT	B-NP
O	1277	1287	measurable	measurable	JJ	I-NP
O	1288	1298	production	production	NN	I-NP
O	1299	1301	of	of	IN	B-PP
O	1302	1307	large	large	JJ	B-NP
O	1308	1313	lipid	lipid	NN	I-NP
O	1314	1322	droplets	droplet	NNS	I-NP
O	1322	1323	,	,	,	O
O	1324	1329	which	which	WDT	B-NP
O	1330	1332	is	be	VBZ	B-VP
O	1333	1334	a	a	DT	B-NP
O	1335	1341	marker	marker	NN	I-NP
O	1342	1344	of	of	IN	B-PP
B-Cell	1345	1351	mature	mature	JJ	B-NP
I-Cell	1352	1358	breast	breast	NN	I-NP
I-Cell	1359	1364	cells	cell	NNS	I-NP
O	1364	1365	.	.	.	O

O	1366	1375	Therefore	Therefore	RB	B-ADVP
O	1375	1376	,	,	,	O
O	1377	1380	our	our	PRP$	B-NP
O	1381	1388	results	result	NNS	I-NP
O	1389	1397	indicate	indicate	VBP	B-VP
O	1398	1402	that	that	IN	B-SBAR
O	1403	1409	emodin	emodin	NN	B-NP
O	1410	1418	inhibits	inhibit	VBZ	B-VP
O	1419	1422	HER	HER	NN	B-NP
O	1422	1423	-	-	HYPH	B-NP
O	1423	1424	2	2	CD	I-NP
O	1424	1425	/	/	SYM	I-NP
O	1425	1428	neu	neu	NN	I-NP
O	1429	1437	tyrosine	tyrosine	NN	I-NP
O	1438	1444	kinase	kinase	NN	I-NP
O	1445	1453	activity	activity	NN	I-NP
O	1454	1457	and	and	CC	O
O	1458	1472	preferentially	preferentially	RB	B-VP
O	1473	1483	suppresses	suppress	VBZ	I-VP
O	1484	1490	growth	growth	NN	B-NP
O	1491	1494	and	and	CC	O
O	1495	1502	induces	induce	VBZ	B-VP
O	1503	1518	differentiation	differentiation	NN	B-NP
O	1519	1521	of	of	IN	B-PP
O	1522	1525	HER	HER	NN	B-NP
O	1525	1526	-	-	HYPH	B-NP
O	1526	1527	2	2	CD	I-NP
O	1527	1528	/	/	SYM	I-NP
O	1528	1531	neu	neu	NN	I-NP
O	1531	1532	-	-	HYPH	O
O	1532	1546	overexpressing	overexpresse	VBG	B-VP
B-Cell	1547	1553	cancer	cancer	NN	B-NP
I-Cell	1554	1559	cells	cell	NNS	I-NP
O	1559	1560	.	.	.	O

O	1561	1566	These	These	DT	B-NP
O	1567	1574	results	result	NNS	I-NP
O	1575	1578	may	may	MD	B-VP
O	1579	1583	have	have	VB	I-VP
O	1584	1600	chemotherapeutic	chemotherapeutic	JJ	B-NP
O	1601	1613	implications	implication	NNS	I-NP
O	1614	1617	for	for	IN	B-PP
O	1618	1623	using	use	VBG	B-VP
O	1624	1630	emodin	emodin	NN	B-NP
O	1631	1633	to	to	TO	B-VP
O	1634	1640	target	target	VB	I-VP
O	1641	1644	HER	HER	NN	B-NP
O	1644	1645	-	-	HYPH	B-NP
O	1645	1646	2	2	CD	I-NP
O	1646	1647	/	/	SYM	I-NP
O	1647	1650	neu	neu	NN	I-NP
O	1650	1651	-	-	HYPH	O
O	1651	1665	overexpressing	overexpresse	VBG	B-VP
B-Cell	1666	1672	cancer	cancer	NN	B-NP
I-Cell	1673	1678	cells	cell	NNS	I-NP
O	1678	1679	.	.	.	O

